EGFR and head and neck squamous cell carcinoma: Cetuximab, a chimeric monoclonal antibody that competes with natural ligands for binding to the extracellular region of EGFR, was approved for HNSCC by the European Medicines Agency (EMA) in 2004 and by the Food and Drug Administration (FDA) in 2006, remaining the only approved targeted agent for HNSCC until the recent introduction of immune checkpoint inhibitors (ICIs) (1, 2, 114).